These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34864812)

  • 1. Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET.
    Uchinomura S; Mitamura K; Norikane T; Yamamoto Y; Oishi A; Hatakeyama T; Miyake K; Nishiyama Y
    Nucl Med Commun; 2022 Mar; 43(3):270-274. PubMed ID: 34864812
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
    Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
    Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
    J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
    Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
    Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
    Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
    Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
    Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
    Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
    Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.
    Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T
    Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients.
    Shi X; Zhang X; Yi C; Wang X; Chen Z; Zhang B
    Clin Nucl Med; 2013 Feb; 38(2):98-102. PubMed ID: 23334122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
    Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
    EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid
    Zhang S; Wang J; Wang K; Li X; Zhao X; Chen Q; Zhang W; Ai L
    Eur J Radiol; 2022 May; 150():110235. PubMed ID: 35290912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and ¹⁸F-fluorodeoxyglucose positron emission tomography.
    Yamashita K; Yoshiura T; Hiwatashi A; Togao O; Yoshimoto K; Suzuki SO; Abe K; Kikuchi K; Maruoka Y; Mizoguchi M; Iwaki T; Honda H
    Neuroradiology; 2013 Feb; 55(2):135-43. PubMed ID: 22961074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.
    Kawase Y; Yamamoto Y; Kameyama R; Kawai N; Kudomi N; Nishiyama Y
    Mol Imaging Biol; 2011 Dec; 13(6):1284-9. PubMed ID: 21042866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
    Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
    Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role Of 18F-FDG PET/CT In Evaluation Of Primary CNS Lymphoma: The Path Less Travelled.
    Usman S; Jain A; Riyami KA; Naumani SP; Sukaiti RA; Shamim MS
    J Pak Med Assoc; 2023 Aug; 73(8):1744-1746. PubMed ID: 37697779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
    Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
    Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.